WO2012097368A2 - Amorces et sondes her3 et her4 pour détecter l'expression de l'arnm her3 et her4 - Google Patents

Amorces et sondes her3 et her4 pour détecter l'expression de l'arnm her3 et her4 Download PDF

Info

Publication number
WO2012097368A2
WO2012097368A2 PCT/US2012/021546 US2012021546W WO2012097368A2 WO 2012097368 A2 WO2012097368 A2 WO 2012097368A2 US 2012021546 W US2012021546 W US 2012021546W WO 2012097368 A2 WO2012097368 A2 WO 2012097368A2
Authority
WO
WIPO (PCT)
Prior art keywords
her4
her3
sample
seq
mrna
Prior art date
Application number
PCT/US2012/021546
Other languages
English (en)
Other versions
WO2012097368A3 (fr
Inventor
Craig Stephens
Original Assignee
Response Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Response Genetics, Inc. filed Critical Response Genetics, Inc.
Publication of WO2012097368A2 publication Critical patent/WO2012097368A2/fr
Publication of WO2012097368A3 publication Critical patent/WO2012097368A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Abstract

Cette invention concerne des procédés, des amorces et des sondes utiles pour détecter la présence de séquences HER1, HER2, HER3 et/ou HER4 ou une combinaison de celles-ci dans un échantillon, plus spécifiquement, pour mesurer leurs niveaux d'expression dans l'échantillon. Cette invention concerne des paires d'amorces oligonucléotidiques et des procédés concernant leur utilisation pour détecter les niveaux d'ARNm HER1, HER2, HER3 et/ou HER4.
PCT/US2012/021546 2011-01-14 2012-01-17 Amorces et sondes her3 et her4 pour détecter l'expression de l'arnm her3 et her4 WO2012097368A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161432933P 2011-01-14 2011-01-14
US61/432,933 2011-01-14

Publications (2)

Publication Number Publication Date
WO2012097368A2 true WO2012097368A2 (fr) 2012-07-19
WO2012097368A3 WO2012097368A3 (fr) 2014-04-10

Family

ID=46507705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/021546 WO2012097368A2 (fr) 2011-01-14 2012-01-17 Amorces et sondes her3 et her4 pour détecter l'expression de l'arnm her3 et her4

Country Status (1)

Country Link
WO (1) WO2012097368A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192652A1 (en) * 2001-06-11 2002-12-19 Danenberg Kathleen D. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US20040157255A1 (en) * 2003-02-06 2004-08-12 David Agus Gene expression markers for response to EGFR inhibitor drugs
US20070065845A1 (en) * 2002-03-13 2007-03-22 Baker Joffre B Gene expression profiling in biopsied tumor tissues
US20080026393A1 (en) * 2006-05-25 2008-01-31 The Board Of Trustees Of The Leland Stanford Junior University Method to produce single stranded DNA of defined length and sequence and DNA probes produced thereby
US20100008975A1 (en) * 2007-03-02 2010-01-14 Amler Lukas C Predicting response to a HER inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192652A1 (en) * 2001-06-11 2002-12-19 Danenberg Kathleen D. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US20070065845A1 (en) * 2002-03-13 2007-03-22 Baker Joffre B Gene expression profiling in biopsied tumor tissues
US20040157255A1 (en) * 2003-02-06 2004-08-12 David Agus Gene expression markers for response to EGFR inhibitor drugs
US20080026393A1 (en) * 2006-05-25 2008-01-31 The Board Of Trustees Of The Leland Stanford Junior University Method to produce single stranded DNA of defined length and sequence and DNA probes produced thereby
US20100008975A1 (en) * 2007-03-02 2010-01-14 Amler Lukas C Predicting response to a HER inhibitor

Also Published As

Publication number Publication date
WO2012097368A3 (fr) 2014-04-10

Similar Documents

Publication Publication Date Title
JP4510915B2 (ja) 上皮増殖因子受容体及びＨＥＲ２−ｎｅｕ遺伝子発現並びにそれらのレベルと生存との相関関係を決定する方法
US8026062B2 (en) Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
EP2361990A1 (fr) Procede permettant de mesurer l'expression du recepteur du facteur de croissance epidermique et du gene HER2-NEU et correlation de ces niveaux d'expression avec les taux de survie
EP3556866B1 (fr) Mutations du gène pik3ca dans les cancers humains
US9216172B2 (en) Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
JP6534930B2 (ja) Ｎｔｒｋ３融合体の検出法
AU2002232409A1 (en) Method of determining epidermal growth factor receptor and Her2-neu gene expression and correlation of levels thereof with survival rates
US20050186215A1 (en) CUDR as biomarker for cancer progression and therapeutic response
US20160002741A1 (en) Method for predicting sensitivity to egfr inhibitor
EP1611890B1 (fr) Méthodes pour évaluer et traiter le cancer
WO2015064621A1 (fr) Nouvelles fusions, et procédé pour leur détection
CA2581430A1 (fr) Compositions et procedes de depistage et de traitement des tumeurs
WO2015072555A1 (fr) Méthode de prédiction de l'efficacité à long terme d'un inhibiteur de vegf
US8216783B2 (en) Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
JP2014501918A (ja) ベバシズマブ併用療法のためのマーカーとしてのａｇｔｒ１
AU2014216135B2 (en) A novel EGFR variant
JP6858563B2 (ja) Ｂｒａｆ変異検出によるｅｇｆｒ阻害剤の効果予測
US10993946B2 (en) Systems and methods for treating cancer
WO2012097368A2 (fr) Amorces et sondes her3 et her4 pour détecter l'expression de l'arnm her3 et her4
KR102055350B1 (ko) 대장암의 항암제 내성 진단용 바이오마커 및 이의 용도
WO2002044423A2 (fr) Procede de determination d'un schema posologique pour la chimiotherapie d'un sujet en dosant l'expression genique des tumeurs primaires
KR101986267B1 (ko) Met 저해제에 대한 감수성 예측용 조성물
JP6486683B2 (ja) Ｈｅｒ２阻害薬を用いた治療に対する応答を予測する方法
US20140356349A1 (en) Biomarkers of resistance to her2 inhibitors
NZ526709A (en) Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12734748

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12734748

Country of ref document: EP

Kind code of ref document: A2